Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Behringwerke AG, a subsidiary of Sanofi, is a German company located in Marburg. The firm produces specialty chemicals and pharmaceutical products.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Meridigen Biotech Co. Ltd. is a Taiwanese private company located in Zhubei that provides biotechnology and management consulting services.

Zhengzhou Guoshi Technology Co., Ltd., established on 2015-07-02, Business scope includes technical consultation for agricultural product processing,technology transfer,Technical Services;Food Technology Development,technical consulting,Technology Transfer and Technical Services;Sales:other chemical products,Instrumentation,other mechanical equipment,Biological product(No vaccine),Pre-packaged food,Healthy food,Packaging Materials.

Shanghai Xingjia Medical Technology Co., Ltd., established on 2016-06-12, Business scope includes medical technology(genetically modified organism,Except human stem cell genetic diagnosis),Biological Technology(genetically modified organism,Except human stem cell genetic diagnosis),Health Supplies,Technology development in the field of computer technology,technical consulting,technology transfer,Technical Services,Business Management Consulting,account Serive,Chemical raw materials(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Daily necessities,Office Supplies,Sales of health care products,Health Management Consulting,Medical device management,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

USV Private Limited is a 55 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Their product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India.

Part of Pluri, Inc., Pluristem Ltd. is a company headquartered in Haifa, Israel, that provides research and development services in the biotechnology field, especially in stem cell research. The firm was founded by Yoram Nathan Drucker. Pluri, Inc. acquired Pluristem Ltd. on June 23, 2003.

LifeCodexx AG, part of Eurofins Scientific SE, is a German company located in Konstanz that develops clinically validated molecular diagnostics.

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. The firm involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Yinfeng Bioengineering Group Co., Ltd., established on 2011-04-19, Business scope includes general items:R&D and application of cell technology;Human stem cell technology development and application;Development of Human Gene Diagnosis and Therapy Technology;Health Consulting Services(Does not include medical services);Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Daily necessities sales;Maternal and baby products sales;Cosmetics Wholesale;Cosmetics Retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Health food sales;Cosmetic production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. In addition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs.

Boya Stem Cell Technology Co. Ltd. develops stem cell technology products. The company is headquartered in Wuxi, China.

Provides research and development on medical sciences and pharmacy

Hubei Yinfeng Dingcheng Biological Engineering Co., Ltd., established on 2013-05-30, Business scope includes licensed projects:Class III Medical Device Leasing(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Human stem cell technology development and application;R&D and application of cell technology;Development of Human Gene Diagnosis and Therapy Technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Remote Health Management Services;Health Consulting Services(Does not include medical services);Cosmetics Wholesale;Cosmetics Retail;Sales of daily chemical products;Healthy food(prepackaged)Sales;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Experimental analysis instrument sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Plakous Therapeutics, a human biologics company that specializes in restorative and regenerative healing. The company advances in regenerative healing by manufacturing bio-therapeutics from the post-delivery human placenta. It establishes a safe and effective therapeutic platform to promote and sustain healing using the placental cytokines and growth factors that orchestrate fetal development and also allow the body to heal itself. Seth Tomblyn and Scott Washburn co-founded the company in 2016 and Headquartered in Winston Salem, North Carolina.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Beijing Kerun Weide Biotechnology Co., Ltd., established on 2007-12-17, Business scope includes biotechnology,environmental technology,Technology research and development of new energy and ecological cycle agriculture,Technical Services,technical consulting,technology transfer,Technology Promotion;Import and export,Technology Import and Export,Agent import and export;sell food.(Enterprises independently choose operating projects according to law,Carry out business activities;Sale of food and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

DePuy Synthes Products, Inc. develops and markets medical products. It offers distal volar Radius, which is designed to treat distal radius fractures, dorsal endoplate, an invasive dorsal nail plate that provides fixed angle support and intramedullary locked fixation with a duplicate and reproducible surgical procedure, spatial subchondral support plate, which is used to treat proximal humeral fractures and Small Bone Fixation System, a percutaneous locked intramedullary nail system for metacarpals and the phalanges. The company was founded on June 22, 2004 and is headquartered in Wilmington, DE.